公开(公告)号：WO1996000577A1

公开(公告)日：1996-01-11

申请号：PCT/US1995008368

申请日：1995-06-28

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  WOLF, David, L. ,  SINHA, Uma

IPC: A61K35/16

CPC classification number: C12N9/6464 ,  A61K38/00 ,  C07K14/745 ,  C12N9/6432 ,  C12N9/647 ,  C12Y304/21006 ,  C12Y304/21069 ,  Y10S514/834 ,  Y10S530/83

Abstract: Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

Abstract translation: 瞬时失活的血液因子的类似物可用于治疗以血栓形成为特征的疾病。 此外，在血清中产生活性血因子但具有延长半衰期的活化血液因子的修饰形式可用于治疗血液病症。 血液因子的这些修饰形式可以是在体内缓慢脱酰基化的酰化形式。

公开(公告)号：EP0631501B1

公开(公告)日：2000-08-30

申请号：EP93908307.7

申请日：1993-03-11

Applicant: COR THERAPEUTICS, INC.

Inventor： SINHA, Uma ,  WOLF, David, L.

IPC: A61K35/78 ,  A61K38/56 ,  A61K38/36 ,  A61K39/395 ,  C07K14/745

CPC classification number: C12N9/6432 ,  A61K38/1709 ,  A61K38/47 ,  C07K14/42 ,  C07K14/745 ,  C07K16/36 ,  C12Y304/21006 ,  Y10S436/827

Abstract: Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an α2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents (SA/Gal/GalNAc binding reagents) as well as other strategies for inhibiting the conversion of Factor X to Factor Xa are useful in treating thrombosis, inflammation and other conditions associated with excess thrombin activity.

公开(公告)号：EP0631501A1

公开(公告)日：1995-01-04

申请号：EP93908307.0

申请日：1993-03-11

Applicant: COR THERAPEUTICS, INC.

Inventor： SINHA, Uma ,  WOLF, David, L.

IPC: A61K38 ,  A61K39 ,  A61P7 ,  A61P29 ,  C07K14 ,  C07K16 ,  C12N9

CPC classification number: C12N9/6432 ,  A61K38/1709 ,  A61K38/47 ,  C07K14/42 ,  C07K14/745 ,  C07K16/36 ,  C12Y304/21006 ,  Y10S436/827

Abstract: Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an α2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents (SA/Gal/GalNAc binding reagents) as well as other strategies for inhibiting the conversion of Factor X to Factor Xa are useful in treating thrombosis, inflammation and other conditions associated with excess thrombin activity.